Building on the results from Part F and monarcHER, pertuzumab was added to abemaciclib and trastuzumab in Part H, reflecting that the standard of care first-line treatment for HER2+ breast cancer includes pertuzumab based on the Phase 3 CLEOPATRA trial (21). Here, ERBB2 is linked to breast cancer.